Uzbekinvest Acquires Risk and Capital Modelling Capabilities From Ultimate Risk Solutions Which Helped Them Attain Stable AM Best Rating
31.7.2024 15:00:00 EEST | Business Wire | Press release
Ultimate Risk Solutions (“URS”) is proud to announce its important contribution into assisting Uzbekinvest Export-Import Insurance Company of Uzbekistan (“Uzbekinvest”) in attaining their stable AM Best credit rating. Through the development of advanced risk models of Uzbekinvest’s insurance and reinsurance lines of business, including catastrophe risk, URS has contributed significantly to this achievement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730430996/en/
Uzbekinvest acquires risk and capital modelling capabilities from Ultimate Risk Solutions (URS) which helped them attain stable AM Best rating (Graphic: Business Wire)
AM Best, a global credit rating agency specializing in the insurance industry, has revised the outlook for Uzbekinvest from negative to stable. The Financial Strength Rating remains at B (Fair), and the Long-Term Issuer Credit Rating at “bb” (Fair). This positive shift reflects Uzbekinvest’s enhanced risk-adjusted capitalization, in part attributed to the sophisticated risk modelling and probable maximum loss estimation facilitated by URS.
URS’s expertise in risk analysis and modelling has been instrumental in this process, showcasing the company’s commitment to delivering tailored risk solutions that enhance the financial stability and performance of its clients.
“Our company, which is the largest insurance and reinsurance provider in Uzbekistan, has made significant advances in the international markets, and is striving to become a global player closely working with AM Best during the process. Risk and capital modelling capabilities offered by URS technologies allow us to keep an eye on the solvency and stability of our global risk portfolio as it continues to grow,” said Rustam Azimov, General Director of Uzbekinvest.
“We are delighted to have supported Uzbekinvest in their journey towards improved financial strength and stability,” said Alex Bushel, Founder and CEO at Ultimate Risk Solutions. “Our team’s dedication to developing sophisticated and comprehensive risk models underscores our mission to empower our clients with the tools necessary for effective risk management and sustainable growth.”
This collaboration marks a significant milestone for both Uzbekinvest and URS, highlighting the importance of innovative risk management strategies in the insurance sector. As URS continues to pioneer in risk modelling and analysis, it remains committed to helping its clients navigate the complexities of risk with confidence and precision.
About Uzbekinvest:
Uzbekinvest Export-Import Insurance Company JSC is a prominent insurance and reinsurance provider in Uzbekistan and globally. The company is committed to offering reliable and comprehensive insurance and reinsurance solutions to its clients, backed by leading modern technologies and a team of dedicated professionals. This company manages total assets valued at USD 164 million and maintains substantial reserves amounting more than USD 106 million, indicating strong financial stability and capacity to cover potential liabilities. Uzbekinvest boasts a robust global footprint, handling risks from 132 countries. It maintains strong partnerships with major reinsurance companies such as Munich Re, Swiss Re, Allianz, Zurich Insurance Company and collaborates with top-tier broking firms including AON, Willis, Marsh, Guy Carpenter, Howden and others to enhance its market reach and service capabilities.
About Ultimate Risk Solutions:
Ultimate Risk Solutions (URS) is a leading provider of risk modelling and analysis technologies and services, offering advanced solutions for insurance companies and financial institutions globally. With a focus on innovation and precision, URS delivers technologies that help clients enhance their risk management practices and achieve their strategic objectives.
Link to AM Best press release regarding revised Uzbekinvest rating outlook:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730430996/en/
Contacts
Sasha Kuznetsov, URS Marketing and Communications Lead | akuznetsov@ultirisk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom